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Aim: Current development of novel systemic agents requires identification and monitoring of extensive
Tenosynovial Giant Cell Tumours (TGCT). This study defines TGCT extension on MR imaging to classify severity.
Methods: In part one, six MR parameters were defined by field-experts to assess disease extension on MR images:
type of TGCT, articular involvement, cartilage-covered bone invasion, and involvement of muscular/tendinous
tissue, ligaments or neurovascular structures. Inter- and intra-rater agreement were calculated using 118 TGCT
MR scans. In part two, the previously defined MR parameters were evaluated in 174 consecutive, not previously
used, MR-scans. TGCT severity classification was established based on highest to lowest Hazard Ratios (HR) on
first recurrence.
Results: In part one, all MR parameters showed good inter- and intra-rater agreement (Kappa≥0.66). In part
two, cartilage-covered bone invasion and neurovascular involvement were rarely appreciated (< 13%) and
therefore excluded for additional analyses. Univariate analyses for recurrent disease yielded positive associations
for type of TGCT HR12.84(95%CI4.60–35.81), articular involvement HR6.00(95%CI2.14–16.80), muscular/
tendinous tissue involvement HR3.50(95%CI1.75–7.01) and ligament-involvement HR4.59(95%CI2.23–9.46).
With these, a TGCT severity classification was constructed with four distinct severity-stages. Recurrence free
survival at 4 years (log rank p < 0.0001) was 94% in mild localized (n56, 1 recurrence), 88% in severe localized
(n31, 3 recurrences), 59% in moderate diffuse (n32, 12 recurrences) and 36% in severe diffuse (n55, 33 re-
currences).
Conclusion: The proposed TGCT severity classification informs physicians and patients on disease extent and risk
for recurrence after surgical treatment. Definition of the most severe subgroup attributes to a universal identi-
fication of eligible patients for systemic therapy or trials for novel agents.
1. Introduction
Tenosynovial Giant Cell Tumour (TGCT) affecting large joints is an
orphan, mono-articular, potentially locally aggressive disease with high
recurrence rates. According to the 2013 WHO classification of tumours
of soft tissue and bone, at the base of growth pattern, a radiological
distinction is made between single nodule (localized-TGCT) and mul-
tiple lesions (diffuse-TGCT). These types differ in their clinical pre-
sentation, response to treatment and prognosis, but histologically, they
seem identical [6–8,16].
Localized-type TGCT is classified as a circumscribed benign small
(between 0.5 and 4 cm) mass [7,15]. Standard treatment of choice is
excision. Subsequently, overall reported recurrence rates are relatively
low: 0–6% [26]. On the contrary, diffuse-type TGCT, previously named
Pigmented VilloNodular Synovitis (PVNS), extensively involves the
synovial membrane and infiltrates adjacent structures [25,26]. Re-
ported recurrence rates of diffuse-TGCT following open synovectomy
are 14% up till 67% and after arthroscopic synovectomy 40% up till
92% [26]. Recurrent or residual disease, frequently requiring multiple,
sometimes mutilating operations, may result in total joint
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arthroplasties, morbidity and loss of quality of life [12,14,27–29]. With
this large variety in disease presentation and recurrence rates, a more
comprehensive and outcome-based classification is asked for. The
emerging era of systemic targeted and multimodality therapies (avail-
able in trial settings) increases the need for a method to select eligible
patients in order to create comparable patient cohorts [20,21,24].
In diagnosing and treating TGCT, magnetic resonance (MR) imaging
is the most distinctive imaging technique [13,16,17,19,30]. MR ima-
ging reveals conspicuous nodular (localized-type) or villous prolifera-
tion of synovium (diffuse-type). However, current literature lacks spe-
cific MR discriminating features to describe or quantify tumour extent
in relation to clinical outcome. Uniform MR descriptions are of utmost
importance for clinical and research purposes. Therefore this study aims
to sub-classify tumour severity especially in diffuse-type TGCT. First, a
group of radiologists and orthopaedic surgeons identified and defined
potentially distinguishing parameters. Second, these MR parameters
were applied on a different study-population to establish TGCT severity
subgroups.
2. Methods
2.1. Part I: identification and evaluation of TGCT specific MR parameters
Using case discussions in expert meetings with two dedicated
musculoskeletal radiologists and three oncological orthopaedic sur-
geons, six MR parameters were selected in relation to anatomical or
surgical landmarks. These parameters were 1 type of TGCT (based on
2013 WHO classification) [6,7], 2 articular involvement, 3 cartilage-
covered bone invasion, 4 involvement of muscular/tendinous tissue, 5
involvement of ligaments and 6 involvement of neurovascular struc-
tures (Fig. 1) (Appendix).
To evaluate usability and reproducibility, 118 MR scans of TGCT
patients, treated at the Leiden University Medical Center (LUMC), were
randomly retrieved (MM). The six MR parameters were evaluated in a
heterogeneous group of TGCT cases as scans included cases of various
large joints (knee (79; 67%), ankle (13; 11%), foot (10; 9%)), severity
subtypes and treatment phases. MR scans were conducted using a 1.5 or
3.0 T unit Philips (Best, The Netherlands) Ingenia MR with dedicated
coils. Standard musculoskeletal scan-protocol included: T1-and T2-
weighted fast spin echo, T1-weighted fat-suppressed post Gd-chelate
contrast and optionally T2* gradient-echo sequences in two planes
(transversal and either sagittal or coronal). To assess inter- and intra-
rater agreement, all MR scans were evaluated by one dedicated mus-
culoskeletal radiologist (DH) and by two dedicated orthopaedic sur-
geons (RW, MS). MR evaluation was blinded to patient characteristics.
Inter-rater agreement and accompanying 95% confidence interval
(95% CI) between three physicians was calculated for all 118 cases by
Fleiss-Kappa (dichotomous outcomes in all parameters, except for ar-
ticular involvement with three outcomes). To evaluate intra-rater
agreement with the accompanying 95% CI (linear weighted kappa), 36
randomly chosen MR scans (31%) were again evaluated three months
after initial evaluation by the senior orthopaedic surgeon (MS).
2.2. Part II: application of TGCT MR parameters
None of the MR scans in part I were used in part II. The combined
TGCT-database of two sarcoma centres in The Netherlands (LUMC and
Radboud University Medical Center (RUMC)) was used to include
consecutive MR scans conducted between 2005 and 2015 (n=283).
MR scan inclusion criteria were: pre-treatment MR scan of histologi-
cally proven TGCT of large joints, conducted in two planes (transversal
and either sagittal or coronal), and open resection as primary treatment
in one of the two participating centers. Large joints were defined as all
joints proximal to and excluding metatarsophalangeal and metacarpo-
phalangeal joints. When TGCT affected the knee, one diagnostic ar-
throscopy prior to open resection was allowed, since tumour extent
would not be affected. Open synovectomy was defined as gross total
resection of disease, either one- or two-staged, without adjuvant
therapy. 174/283 Patients met the inclusion criteria (Fig. 2). Median
follow-up was 36 (IQR 21–60) months, maximum follow-up 12 years
after primary surgery.
The senior author (MS) evaluated the six defined MR parameters
(part I) on these pre-treatment scans (77 LUMC, 97 RUMC). MR eva-
luation was blinded to patient characteristics and clinical outcome.
Patient and tumour characteristics were gathered: gender, localization
(affected joint), age at time of the MR scan, date of open synovectomy,
first local recurrence and date of first recurrence (on MR imaging), and
date of last follow-up. Median follow-up was calculated from date of
primary surgery to date of last clinical follow-up, including inter-
quartile range (IQR). Recurrence free survival was calculated from date
of surgery to recurrent disease or last contact.
As outcome, first recurrence was defined as new disease presence
after synovectomy or growing residual disease (diagnosed on follow-up
MR scan). Proposed risk factors were gender, localization (knee versus
other joints) and age at the time of the MR scan (below or above 40
years). Hazard ratios (HRs) and their corresponding 95% CI were es-
timated for risk factors and MR parameters (part I) by univariate and
multivariate Cox regression analyses to estimate the relation on re-
current disease. Since estimating HR is unreliable for rarely present MR
parameters, only parameters with an adequate number of presence
(minimum of 20%) were used for additional analyses. Recurrence free
survival close to median time of follow-up was calculated by Kaplan
Meier analyses and log rank test. Time zero was defined as date of
primary open synovectomy.
At the base of HRs with positive associations of risk factors and MR
parameters on first recurrences, the TGCT severity classification was
established. The TGCT subgroup flow chart started with the MR para-
meter with highest HR, followed by descending HRs. Statistical Package
for Social Statistics (SPSS) version 23 was used for analyses.
2.3. Ethical statement
This study was approved by the institutional review board from our
institution (registration number P13.029). No funding was received.
3. Results
3.1. Part I: evaluation of TGCT specific MR parameters
Inter-rater agreements for type of TGCT, articular involvement,
cartilage-covered bone invasion, and involvement of muscular/tendi-
nous tissue, ligaments or neurovascular structures were 0.71; 0.68;
0.66; 0.67; 0.75 and 0.73, respectively. Intra-rater agreements for these
parameters were between 0.72 and 1.00 (Table 1). Since inter- and
intra-rater agreements were good [5] for these six MR features, all
parameters were considered viable to use for TGCT subgroup analyses.
3.2. Part II: application of TGCT MR parameters
Out of 174MR scans, the knee was affected most (122; 70%), fol-
lowed by the ankle (20; 12%) (Table 2). In univariate analyses, none of
the proposed risk factors were associated with recurrent disease
(p > 0.37) (Table 3) and consequently not used for further analyses.
Both MR parameters cartilage-covered bone invasion and involvement
of neurovascular structures were rarely seen on MR images (< 13%)
and in accordance with our exclusion criteria not used for additional
analyses. In univariate analyses, the remaining four MR parameters
were associated with recurrent disease (p < 0.002) (Table 3); strongest
association was seen in diffuse-type compared with localized-type (HR
12.84 (95%CI 4.60–35.81)), subsequently intra- and extra-articular
involvement compared with extra-articular (HR 6.00 (95%CI
2.14–16.80)) and involvement of muscular/tendinous tissue or
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Fig. 1. Definition of six TGCT specific MR parameters
TGCT-type
a. Localized-type on a sagittal PD-weighted FSE MR image of a 49 year old female patient. Localized-TGCT is defined according to WHO as a well circumscribed
nodular lesion at synovial lining of bursa, joint or tendon sheath.
b. Diffuse-type on a sagittal PD-weighted FSE MR image of a 24 year old male patient. Diffuse-TGCT is defined as a multinodular lesion involving a larger part or
multiple compartments of the synovial lining.
Articular involvement
c. Intra-articular well circumscribed lesion on posterior cruciate ligament on a PD-weighted FSE MR image of a 18 year old female patient. Intra-articular in-
volvement is defined as TGCT involvement inside synovial lining of joint.
d. Extra-articular involvement, along gastrocnemius muscle insertion, on a sagittal T1-weighted FSE MR image of a 33 year old male patient. Extra-articular
involvement is defined as TGCT involvement outside synovial lining of the joint.
e. Both intra- and extra-articular involvement on a sagittal T1-weighted fat-suppressed MR image after intravenous administration of gadolinium of a 63 year old
female patient with TGCT. Extensive tumour growth anterior and posterior.
Cartilage-covered bone invasion
f. Cartilage covered bone invasion on a sagittal T1-weighted FSE MR image of a 59 year old male patient. Square presents cartilage covered bone, defined as clear
invasion of bone through cartilage; not only touch cartilage. Circle presents not-cartilage covered bone invasion.
Muscular/tendinous tissue involvement
g. Muscular/tendinous tissue involvement, anterior vastus medialis muscle and posterior hamstrings tendon, on a sagittal T1-weighted fat-suppressed MR image after
intravenous administration of gadolinium of a 63 year old female patient with TGCT. Muscular/tendinous tissue is defined as involvement of muscular/tendinous
tissue or> 180° encagement of tendon/muscle.
Ligament involvement
h. Cruciate ligament enhancement on a sagittal T1-weighted fat-suppressed MR image after intravenous administration of gadolinium of a 64 year old male patient.
Ligament involvement is defined as involvement of ligament or> 180° encagement of ligament.
Neurovascular structures involvement
i.Popliteal artery encagement on an axial PD-weighted FSE MR image of a 62 year old female patient, referred to a tertiary sarcoma center with extensive TGCT.
Neurovascular involvement is defined as>180° encagement of the artery or nerve.
FSE, Fast Spin Echo; PD, Proton DensityFigure e & g is the same female patient.
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ligaments compared with no involvement (HR 3.50 (95%CI 1.75–7.01),
HR 4.59 (95%CI 2.23–9.46), respectively).
Multivariate analyses for MR parameters did not show individual
positive association, except for parameter type of TGCT (supplementary
material I).
Four TGCT severity subtypes were established using a flowchart that
begins with the parameters with highest HR (parameter type of TGCT),
followed by parameters with descending HRs. These four subtypes
showed a clinically relevant or significant prognostic value for re-
current disease and were classified as: mild localized (n56, 1 recur-
rence), severe localized (n31, 3 recurrences), moderate diffuse (n32, 12
recurrences) and severe diffuse (n55, 33 recurrences).
1. Mild localized contained localized-type, either intra- or extra-ar-
ticular involvement without involvement of muscular/tendinous
tissue/ligaments.
2. Severe localized included localized-type, either intra- or extra-ar-
ticular lesions and either or both involvement of muscular/tendi-
nous tissue/ligaments.
3. Moderate diffuse comprised diffuse-type with intra- and/or extra-
articular disease without and involvement of muscular/tendinous
tissue/ligaments.
4. Severe diffuse was diffuse-type including intra- and extra-articular
involvement and involvement of at least one of the three structures
(muscular/tendinous tissue/ligaments) (Fig. 3).
Recurrence free survival at 4 years (close to median follow-up dif-
fuse-type) for the four patient groups according to the new MR subtypes
descended from 94% in mild localized, to 88% in severe localized, to
59% in moderate diffuse and to 36% in the least favorable subtype,
severe diffuse. Median time to local recurrence in moderate diffuse and
severe diffuse subtypes was 29.5 (IQR 14.5–48.0) and 22.0 (IQR
11.8–33.5) months, respectively. Majority of recurrent disease cases
were already treated with a re-operation (32/49, 65%). One patient,
classified as severe diffuse, died of another disease, after four months
and was censored at that time. Novel MR based TGCT severity and
associated Kaplan Meier survival curves presented significant difference
between the four patient groups (log rank p < 0.0001) and additional
differentiation compared with solely sub-classifying in localized- and
diffuse-TGCT (Fig. 4 and supplementary material II).
4. Discussion
This is the first study to define severity subtypes in Tenosynovial
Giant Cell Tumours (TGCT) based on a combination of four MR imaging
parameters. These subtypes correlate with a spectrum of disease se-
verity ranging from low to high risk of local recurrence after surgical
intervention.
Within this present era of systemic targeted and multimodality
therapies (available in trial settings) in TGCT, standalone surgical re-
section cannot be regarded the gold standard anymore for more severe
Fig. 2. Inclusion flowchart part II TGCT severity classification.
Table 1
Inter- and intra-rater agreement (kappa) in six MR parameters.
Table 2
TGCT MR scan demographics.
Cases (%) Cases localized-
TGCT (%)
Cases diffuse-
TGCT (%)
Total number of MR
scans
174 87 87
Gender
Female 105 (60) 33 (38) 36 (41)
Male 69 (40) 54 (62) 51 (59)
Median age at MR scan
(IQR)
37 (26–48)
years
37 (24–47) years 36 (26–49) years
Localization
Knee 122 (70) 63 (72) 59 (68)
Hip 8 (5) 0 (0) 8 (9)
Ankle 20 (12) 10 (11) 10 (11)
Foot 9 (5) 5 (6) 4 (5)
Elbow 6 (3) 4 (5) 2 (2)
Other 9 (5) 5 (6) 4 (5)
Median follow-up
(IQR)
36 (21–60)
months
32 (17–56)
months
41 (24–63)
months
Total number of recurrences
Recurrent disease 49 (28) 4 (5) 45 (52)
No recurrent disease 125 (72) 83 (95) 42 (48)
IQR, interquartile range.
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cases [22]. Because of the lack of clear-cut boundaries in diffuse-TGCT,
complete resection is difficult and at times technically impossible or
undesirable with joint function preservation and quality of life in mind.
In patients with locally advanced TGCT or (multiple) recurrence(s),
systemic therapies targeting the CSF1/CSF1R axis have been in-
vestigated; less potent drugs as nilotinib and imatinib [2,9], and more
specific inhibitors as emactuzumab (RG7155), pexidartinib (PLX3397)
and cabiralizumab (FPA008). Emactuzumab (N=29) had an overall
response rate of 86% (two patients with a complete response) and a rate
of disease control of 96%, including a significant functional and
symptomatic improvement (median follow up 12 months) [3]. In a
randomized, placebo-controlled phase 3 study, pexidartinib showed an
improved overall response rate by RECIST: 39% in the pexidartinib-
group (N=61) and 0% of placebo-group (N=59), after median six
months follow-up [23]. The preliminary results with cabiralizumab
(N=22) are consistent, with radiographic response and improvement
in pain and function in five out of 11 patients 28 [21]. However, long
term efficacy data have not yet been reported with these newer agents.
Patient inclusion for these trials is very heterogeneous. A strict pa-
tient selection is desirable, to accurately evaluate effect of these treat-
ments. At present, patient selection for trial inclusion is established by
preference of treating physician and might differ per center. Defining
more aggressive TGCT subtypes and including these uniformly defined
patients into trials would more adequately investigate the effect and
toxicities of treatment [11]. In this study, we propose to include pa-
tients defined with ‘severe diffuse’ TGCT subtype. Monitoring the effect
of systemic therapy also benefits from clear agreements on parameters.
Uniform MR descriptions are of utmost importance for clinical and
research purposes. Thus far, no well-defined tumour parameters exist.
Definition of unambiguous MR criteria is challenging, because of the
rarity of the tumour and small number of heterogeneous cases, variety
of joints involved, different disease severity as well as several treatment
modalities [4,6]. So far, MR imaging has shown to be the best dis-
criminating method to evaluate TGCT [10,16]. In our study, six ob-
jective clinically relevant MR parameters were defined in relation to
anatomical or surgical landmarks. According to our exclusion criteria
for the development of the severity classification, parameters cartilage
covered bone invasion and neurovascular involvement showed in-
adequate number of presence and were therefore not used. However, in
larger case series these two parameters might correlate with more ag-
gressive disease and hence a higher recurrence rate.
To date, no radiology-based TGCT severity classification exists.
Subdividing between localized- and diffuse-TGCT seems an over-
simplification that fails to estimate differences in recurrent rates for
individual patients. Murphey et al. presented an extensive review of
different TGCT features on several imaging techniques, without relating
these features to disease severity, treatment or recurrences [16]. Van
der Heijden et al. further sub-classified diffuse-TGCT affecting the knee
in 30 patients into mild or severe, without linking to recurrent disease.
Mild diffuse-TGCT was defined as involvement of either anterior or
posterior compartment of the knee, with the cruciate ligaments as
boundary. Severe diffuse-TGCT was defined as involvement of both
compartments, with or without extra-articular extension [27]. In con-
trast to most literature, we selected a homogeneously treated patient
Table 3
Risk of recurrence on MR imaging; univariate analyses in proposed risk factors
and four MR parameters.
n (%) Hazard ratio (95% CI) P
Gender
Male 69 (40) 1.29 (0.74–2.27) 0.37
Female 105 (60) 1
Age
<40 years 91 (52) 1.15 (0.66–2.02) 0.63
>40 years 83 (48) 1
Localization
Knee 122 (70) 1.15 (0.63–2.12) 0.65
Other joint 52 (30) 1
TGCT-type
Diffuse 87 (50) 12.84 (4.60–35.81) < 0.000
Localized 87 (50) 1
Articular involvement
Intra-articular 59 (34) 1.11 (0.31–3.95) 0.87
Intra- and extra-articular 75 (43) 6.00 (2.14–16.80) 0.001
Extra-articular 40 (23) 1
Muscular/tendinous tissue involvement
Yes 90 (52) 3.50 (1.75–7.01) < 0.000
No 84 (48) 1
Ligament involvement
Yes 86 (49) 4.59 (2.23–9.46) < 0.000
No 88 (51) 1
Fig. 3. TGCT severity classification, containing four severity subtypes: mild localized, severe localized, moderate diffuse and severe diffuse. RFS 4y, Recurrence free
survival at 4 years.
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population to develop four severity subtypes, by only including patients
initially treated with an open synovectomy.
In line with most papers, especially papers on trial medication, and
based on clinical practice, we included all large joints to sub-classify
disease severity for TGCT. Prior research did not show a (significant)
difference in recurrence rates for both localized and diffuse disease
when comparing the knee with other joints [1,4,18,26]. A recent TGCT
incidence calculation study showed a predominance of the knee in 46%
in localized- and 64% in diffuse-type (excluding digits) [15], in line
with our overrepresentation of the knee of 70%. In the future, a TGCT
severity classification focused on the knee would contain more detailed
knee-specific MR parameters and equal treatment approaches.
Limitations to this study: primary, the resulting HRs had wide
confidence intervals, indicating low precision in the estimates. This is
likely related to the relatively small sample size, given that the patients
were divided into several groups based on the MR parameters.
Secondly, because of the relatively small number of recurrences in se-
verity subtypes mild localized (n 1) and severe localized (n 3), Hazard
Ratios may be unreliable. Therefore, it was not feasible to estimate a
cox model and to generate a true prediction model. Additionally, lo-
calized-TGCT is known to have few recurrences and often remains
without clinical complaints after resection. In both sarcoma centers,
patients are therefore discharged from follow-up after the first follow-
up post-surgery and requested to return again when clinical complaints
present. In our analyses, 31 localized-type patients were censored at
date of last clinical follow-up within the first two years in survival curve
(Fig. 4). Less often, patients with diffuse-type have also lacked follow-
up (13 censored first two years). It could be assumed that these patients
did not have complaints and recurrent disease. Furthermore, in study
part two (establishing TGCT subtypes), newest included MR scans ori-
ginated from 2015. These cases had a maximum follow-up of two years.
Since it is known that local recurrence might develop years after initial
surgery [6,18,29], in our study a median of 29.5 in moderate diffuse
and 22.0 months in severe diffuse-TGCT subtypes, underestimation of
recurrence free survival could be present. Finally, even though quite a
large number of MR scans (174) were used in development of the se-
verity classification, in larger case-series including long follow-up time,
it might be possible to differentiate further in disease severity and as-
sess additional subtypes.
To conclude, in reporting TGCT affecting large joints on MR ima-
ging, six parameters are helpful in discriminating disease extent.
Patients can be accurately monitored by using these MR parameters.
With respect to recurrence, a combination of four MR parameters
classifies patients into one of four severity subtypes, presented with
distinct recurrence free survival rates. In the era of personalized med-
icine, treatment is individualized for each patient depending on the
extent of disease. Because histopathological prognostic factors are
lacking, sub-classification of TGCT on MR imaging is a potential tool to
stratify future patient prognosis and identify candidates for targeted
therapies, thereby aiding with the decision in daily practice.
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